<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901015</url>
  </required_header>
  <id_info>
    <org_study_id>P11/34_EVACO</org_study_id>
    <nct_id>NCT02901015</nct_id>
  </id_info>
  <brief_title>Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning</brief_title>
  <acronym>EVACO</acronym>
  <official_title>Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning (EVACO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional, multicenter, and longitudinal study, of a cohort of patients with
      schizophrenia, evaluated on social cognition, neurocognition, symptoms, functioning with 12
      months interval.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is evaluation and validation of social cognition battery, characterizing
      the psychometric properties (validity, sensitivity to change) measures in a cohort of
      schizophrenic patients. Other objective is to demonstrate that the various components
      operating at T0 and T12 months of schizophrenic patients, as an external validator, are
      significantly explained by social cognition performance given the third known factors :
      neuropsychological, sociodemographic, disease course, and clinical status. Search and model
      relationships between the measured variables.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2013</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cognitive skills</measure>
    <time_frame>Day 0, Month 12</time_frame>
    <description>Change in the aggregates (average) of standardized performance levels : z-scores of Theory of mind (V-COMICS, V-SIR, SPEX), z-scores of empathy (QCAE), z-scores of facial affect recognition (TREF), z-scores of metacognition (V-COMICS meta), Intelligence quotient (WAIS-III), z-scores of treatment speed, z-scores of memory spans, z-scores of verbal memory, z-scores of visual memory, z-scores of attention/vigilance, z-scores of divided attention, z-scores of executive functions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Functioning</measure>
    <time_frame>Day 0, Month 12</time_frame>
    <description>Change in the aggregates (average) of standardized functioning assessment: z-scores of social functioning, z-scores of general functioning (PSPS), and z-scores of help acceptance subscales (M-SEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Psychotic symptoms</measure>
    <time_frame>Day 0, Month 12</time_frame>
    <description>Change in the aggregates (average) of standardized symptomatology and clinical dimensions: z-scores of Schizophrenic syndromes, depressive syndrome and manic syndrome (PANSS), z-scores of observance scale (MARS/BARS), z-scores of insight (Birchwood), z-scores of antipsychotic medication doses</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Schizophrenic patients group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schizophrenic patients group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>80 patients evaluated in the Fondamental Expertise Center for schizophrenia Network (8 centers in France).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment battery A</intervention_name>
    <description>Social cognition tests version &quot;A&quot; are administered to the patients</description>
    <arm_group_label>Schizophrenic patients group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Assessment battery B</intervention_name>
    <description>Social cognition tests version &quot;B&quot; are administered to the patients</description>
    <arm_group_label>Schizophrenic patients group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia or schizoaffective disorder

          -  Age &gt; 18 years and &lt; 65 years

          -  Patient's state allows cognitive and neuropsychological assessment

          -  Affiliated to a social security system (beneficiary or legal).

          -  Informed consent signature (patients under guardianship may be included with written
             permission from their legal representative).

        Exclusion Criteria:

          -  Alcohol dependence or current toxic

          -  Electroconvulsivotherapy (less than 6 months)

          -  Serious head trauma (become unconscious), epilepsy or neurological disorder
             significant or evolutionary

          -  Invalidating and uncorrected visual disorder

          -  Invalidating and not paired hearing

          -  Actually hospitalized under constraint

          -  Patient not able to come to different evaluations, or who plan to change medical care
             in the following year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes Isère</name>
      <address>
        <city>Saint Egrève</city>
        <zip>38120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Eric BRUNET</investigator_full_name>
    <investigator_title>Investigator coordinator</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

